Critical Survey: Anacor Pharmaceuticals (ANAC) & The Competition

Anacor Pharmaceuticals (NASDAQ: ANAC) is one of 188 public companies in the “Biotechnology & Medical Research” industry, but how does it compare to its rivals? We will compare Anacor Pharmaceuticals to similar businesses based on the strength of its institutional ownership, profitability, analyst recommendations, dividends, earnings, risk and valuation.

Analyst Ratings

This is a summary of recent recommendations for Anacor Pharmaceuticals and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anacor Pharmaceuticals 0 0 0 0 N/A
Anacor Pharmaceuticals Competitors 540 2444 6663 127 2.65

As a group, “Biotechnology & Medical Research” companies have a potential upside of 14.31%. Given Anacor Pharmaceuticals’ rivals higher possible upside, analysts clearly believe Anacor Pharmaceuticals has less favorable growth aspects than its rivals.

Insider and Institutional Ownership

50.0% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 14.7% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Anacor Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Anacor Pharmaceuticals -92.08% -133.71% -38.09%
Anacor Pharmaceuticals Competitors -4,559.29% -564.66% -43.81%

Volatility and Risk

Anacor Pharmaceuticals has a beta of 1.53, meaning that its stock price is 53% more volatile than the S&P 500. Comparatively, Anacor Pharmaceuticals’ rivals have a beta of 1.55, meaning that their average stock price is 55% more volatile than the S&P 500.

Earnings and Valuation

This table compares Anacor Pharmaceuticals and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Anacor Pharmaceuticals N/A N/A -68.41
Anacor Pharmaceuticals Competitors $217.29 million -$39.39 million -65.48

Anacor Pharmaceuticals’ rivals have higher revenue, but lower earnings than Anacor Pharmaceuticals. Anacor Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Anacor Pharmaceuticals rivals beat Anacor Pharmaceuticals on 5 of the 8 factors compared.

About Anacor Pharmaceuticals

Anacor Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform. Its lead product development candidate is crisaborole topical ointment, approximately 2%, a non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the treatment of mild-to-moderate atopic dermatitis and psoriasis. Its product, KERYDIN (tavaborole) topical solution, approximately 5%, is an oxaborole antifungal approved by the United States Food and Drug Administration (FDA) for the topical treatment of onychomycosis of the toenails. It also has a pipeline of other internally discovered topical and systemic boron-based compounds in early-stages of research and development, which include AN3365. Its compound, AN5568 (SCYX-7158), is licensed to Drugs for Neglected Diseases initiative (DNDi) for the treatment of human African trypanosomiasis.

Receive News & Ratings for Anacor Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anacor Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply